Pfizer's Lipitor Gains Prevention Indication For Patients With Normal Cholesterol
This article was originally published in The Pink Sheet Daily
Executive Summary
The approval gives Pfizer a new indication to promote as Merck/Schering rolls out the Zocor/Zetia combination therapy Vytorin. Lipitor's new indication is based on results of the ASCOT study, which showed a 36% reduction in relative risk of heart attack in patients with normal to borderline cholesterol but high blood pressure and risk factors for heart disease.
You may also be interested in...
Pfizer’s Lipitor Gains Stroke, Heart Attack Indication In Diabetic Patients
Atorvastatin’s expanded label also includes an indication for reducing the risk of stroke in patients without evidence of heart disease but with multiple risk factors other than diabetes.
Pfizer’s Lipitor Gains Stroke, Heart Attack Indication In Diabetic Patients
Atorvastatin’s expanded label also includes an indication for reducing the risk of stroke in patients without evidence of heart disease but with multiple risk factors other than diabetes.
Merck/Schering's Vytorin Priced At 22% Discount To Pfizer's Lipitor
The ezetimibe/simvastatin combination is priced at a 39% discount to the three highest doses of Merck's Zocor. Vytorin will launch in August at a wholesale acquisition cost of $2.34 per day.